Latest Corporate Development News

State Gas Limited has voluntarily suspended trading on the ASX as it finalises negotiations on a significant asset sale and clarifies related R&D incentive claims. The suspension will last until an announcement expected by 30 March 2026.

Great Dirt Resources has appointed seasoned mining executives Tim Laneyrie and Sam Brooks to its leadership team, aiming to accelerate exploration and strategic acquisitions. These moves coincide with governance changes and a new corporate address, signalling a fresh phase for the ASX-listed explorer.

Neurizon Therapeutics announces the resignation of CEO Dr Michael Thurn, with Executive Chair Sergio Duchini stepping in temporarily as the company embarks on a global hunt for new leadership.

MC Mining reports a modest improvement in half-year losses despite declining coal production and revenue, while advancing its Makhado Project and suspending Uitkomst operations to curb cash losses.

Titan Minerals has reported significant wide zones of gold-silver-copper porphyry mineralisation at its Kaliman target within the Dynasty Gold Project, following a 25,000m drilling campaign in 2025. This breakthrough is set to underpin an imminent Mineral Resource update expected in late Q1 2026.

Ragusa Minerals’ recent site visit to its Purple Pansy Project in Arizona confirms promising high-grade manganese oxide mineralisation, setting the stage for accelerated exploration activities.

New Age Exploration appoints seasoned geologist Kirby Johnson as CEO and acquires the promising Wallah Silver Project in NSW, complementing positive drilling results at its Wagyu Gold Project in Pilbara.

MCS Services Limited has reported a significantly reduced half-year loss and announced plans to sell its Highways Traffic subsidiary, aiming to strengthen its financial position amid ongoing challenges.

Radiopharm Theranostics reported a 44% increase in net loss to $27 million for the half-year ended December 2025, driven by expanded R&D spending. The company bolstered its cash reserves through a $35 million placement while progressing multiple clinical trials across its radiopharmaceutical pipeline.

Racura Oncology reported a $4.1 million loss for H1 FY26, reflecting heavy investment in clinical trials and intellectual property. The company also boosted cash reserves through capital raises and rebranded from Race Oncology.

Entropy Neurodynamics reports a 14.8% reduction in half-year losses while progressing a pioneering clinical trial for Binge Eating Disorder using its proprietary psychedelic drug TRP-8803. The company also secured $6.1 million in new funding and strategic collaborations to enhance its neuropsychiatry platform.

Tribeca Global Natural Resources Limited reported a remarkable turnaround with a $69.5 million net profit for the half-year ended December 2025, alongside a fully franked dividend declaration. The company’s net tangible asset per share more than doubled, reflecting strong commodity market dynamics and strategic investment execution.